Nonsynonymous ATM mutations occur in approximately 11% of NSCLC samples and frequently co-occur with KRAS mutations, while showing mutual exclusivity with EGFR, TP53, and KEAP1 within the KRAS-mutant subset from clinicogenomic database (CGDB). This evidence concerns the gene TP53 and non-small cell lung carcinoma.